EANS-Adhoc: SYGNIS Pharma AG / SYGNIS Announces Prolongation of Standby Equity Distribution Agreement

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

31.07.2012

Ad hoc-Release according to § 15 WpHG SYGNIS Announces Prolongation
of Standby Equity Distribution Agreement

Heidelberg, July 31, 2012 - SYGNIS Pharma AG (Frankfurt:
LIOK; ISIN DE000A1E9B74; Prime Standard) has ahead of schedule
agreed a prolongation of the standby equity distribution agreement
(SEDA) with YA Global Master SPV LTD (YA Global) effective from
November 1, 2012 for further three years with unchanged
conditions. The agreement provides SYGNIS Pharma AG with the
option to request YA Global, during the term of the agreement, to
subscribe for newly issued SYGNIS shares from the Company's
authorized capital in tranches of up to EUR 500,000 each. The
subscription price of the new shares will be determined at 95% of
the lowest volume-weighted average price of one of the five trading
days following the date of the relevant draw down notice.

The total value of this equity facility aggregates to up to
EUR 10 million, provided that the aggregate number of shares issued
to YA Global shall not exceed 9,9% of SYGNIS Pharma AG's
share capital. YA Global can either accumulate these shares or
place them in the market. However, YA Global is committed not to
short sell or enter into any hedging transactions related to the
particular company stock.

The prolongation is subject to the condition precedent that the
German Federal Financial Supervisory Authority (Bundesanstalt für
Finanzdienstleistungsaufsicht) grants an exemption from the
obligations pursuant to sec.35 of the German Takeover Act
(Wertpapiererwerbs- und Übernahmegesetz)toGenetrix, A.B., and
parties affiliated or acting in concert with Genetrix, A.B.,
regarding the proposed contribution of X-Pol into SYGNIS Pharma AG
in particular to submit a mandatory tender offer to the
existing shareholders of SYGNIS Pharma AG in connection with
the related capital increase of SYGNIS Pharma AG.

**** end of ad hoc ****
For further information please contact:

|SYGNIS Pharma AG | |
| |
|Peter Willinger | |
| |
|Tel: +49 6221 454 836 | |
| |
|Email: peter.willinger@sygnis.de | |
| |

### Disclaimer

This publication is intended for information only and constitutes
neither an offer to sell nor an invitation to buy securities. Some
statements included in this press release, relating neither to
proven financial results nor other historical data, should be
viewed as forward-looking, i.e. not definite. Such statements are
mainly predictions of future results, trends, plans or goals.
These statements should not be considered to be total guarantees
since given their very nature they are subject to known and
unknown risks and imponderability and can be affected by other
factors as a consequence of which the actual results, plans and
goals of SYGNIS Pharma AG may deviate greatly from the
established conclusions or implied predictions contained in
such statements. SYGNIS does not undertake to publicly update
or revise these statements in the light of new information or
future results or for any other reason. ###

Further inquiry note:
Marc Risch
Telefon: +49 (6221) 454 - 737
E-Mail: Marc.Risch@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
Stuttgart, regulated dealing/prime standard: Frankfurt
language: English